Walvax Biotechnology Co., Ltd.
300142
株式のランク
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
株価
$1.87
時価総額
$2.98B
変化（1日）
-3.71%
変化（1年）
14.73%
国
CN
取引 Walvax Biotechnology Co., Ltd. (300142)
カテゴリー
Healthcare
Walvax Biotechnology Co., Ltd.（300142）の発行済株式数
June 2026 時点の発行済株式数 1.60B
Walvax Biotechnology Co., Ltd. の最新の財務報告および株価によると、現在の発行済株式数は 1.60B です。December 2024 の終わりには、同社は 1.60B 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Walvax Biotechnology Co., Ltd.（300142）の発行済株式数の履歴（2007 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 1.60B | 0.00% |
| 2025 | 1.60B | 0.02% |
| 2024 | 1.60B | -0.06% |
| 2023 | 1.60B | -0.07% |
| 2022 | 1.60B | -0.01% |
| 2021 | 1.60B | 3.56% |
| 2020 | 1.55B | 0.52% |
| 2019 | 1.54B | 0.05% |
| 2018 | 1.54B | 0.01% |
| 2017 | 1.54B | 9.09% |
| 2016 | 1.41B | 0.55% |
| 2015 | 1.40B | -2.28% |
| 2014 | 1.43B | -0.18% |
| 2013 | 1.44B | 2.07% |
| 2012 | 1.41B | 0.00% |
| 2011 | 1.41B | 15.17% |
| 2010 | 1.22B | 16.33% |
| 2009 | 1.05B | 66.06% |
| 2008 | 632.71M | 573.74% |
| 2007 | 93.91M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 434.78M | -72.82% |
DE
|
|
| 434.78M | -72.82% |
DE
|
|
| 1.56B | -2.30% |
JP
|
|
| 233.66M | -85.39% |
CH
|
|
| 2.40B | 50.02% |
IN
|
